JP2021501572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501572A5 JP2021501572A5 JP2020521986A JP2020521986A JP2021501572A5 JP 2021501572 A5 JP2021501572 A5 JP 2021501572A5 JP 2020521986 A JP2020521986 A JP 2020521986A JP 2020521986 A JP2020521986 A JP 2020521986A JP 2021501572 A5 JP2021501572 A5 JP 2021501572A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- artificial nucleic
- utr
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 57
- 108020004707 nucleic acids Proteins 0.000 claims 46
- 102000039446 nucleic acids Human genes 0.000 claims 46
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 229960005486 vaccine Drugs 0.000 claims 13
- 108091026890 Coding region Proteins 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 11
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 125000002091 cationic group Chemical group 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 4
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 4
- 229940029575 guanosine Drugs 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 108010033040 Histones Proteins 0.000 claims 3
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 101150009643 PSMB3 gene Proteins 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101150077194 CAP1 gene Proteins 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 claims 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 2
- 108091036407 Polyadenylation Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- 150000003838 adenosines Chemical class 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000002009 allergenic effect Effects 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 101150026538 rps9 gene Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 101150033839 4 gene Proteins 0.000 claims 1
- 101150096316 5 gene Proteins 0.000 claims 1
- 102100040768 60S ribosomal protein L32 Human genes 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 101100255144 Caenorhabditis elegans rps-9 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101150064023 HSD17B4 gene Proteins 0.000 claims 1
- 101000672453 Homo sapiens 60S ribosomal protein L32 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 208000037919 acquired disease Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000961 alloantigen Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000006384 oligomerization reaction Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229920002851 polycationic polymer Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000005829 trimerization reaction Methods 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 229940045145 uridine Drugs 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189376A JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2025090961A JP2025131658A (ja) | 2017-10-19 | 2025-05-30 | 新規な人工核酸分子 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2017/076741 | 2017-10-19 | ||
| EPPCT/EP2017/076775 | 2017-10-19 | ||
| EP2017076775 | 2017-10-19 | ||
| EP2017076741 | 2017-10-19 | ||
| EPPCT/EP2018/057552 | 2018-03-23 | ||
| PCT/EP2018/057552 WO2018172556A1 (en) | 2017-03-24 | 2018-03-23 | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP2018076185 | 2018-09-26 | ||
| EPPCT/EP2018/076185 | 2018-09-26 | ||
| PCT/EP2018/078453 WO2019077001A1 (en) | 2017-10-19 | 2018-10-17 | NEW ARTIFICIAL NUCLEIC ACID MOLECULES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189376A Division JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501572A JP2021501572A (ja) | 2021-01-21 |
| JP2021501572A5 true JP2021501572A5 (https=) | 2021-11-25 |
Family
ID=66173912
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521986A Pending JP2021501572A (ja) | 2017-10-19 | 2018-10-17 | 新規な人工核酸分子 |
| JP2023189376A Pending JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2025090961A Pending JP2025131658A (ja) | 2017-10-19 | 2025-05-30 | 新規な人工核酸分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189376A Pending JP2024012523A (ja) | 2017-10-19 | 2023-11-06 | 新規な人工核酸分子 |
| JP2025090961A Pending JP2025131658A (ja) | 2017-10-19 | 2025-05-30 | 新規な人工核酸分子 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220233568A1 (https=) |
| EP (1) | EP3697912A1 (https=) |
| JP (3) | JP2021501572A (https=) |
| KR (2) | KR20250138817A (https=) |
| CN (1) | CN111630173A (https=) |
| AU (2) | AU2018351481B2 (https=) |
| BR (1) | BR112020004351A2 (https=) |
| CA (1) | CA3073634A1 (https=) |
| IL (2) | IL321714A (https=) |
| MX (2) | MX2020003995A (https=) |
| RU (1) | RU2020115287A (https=) |
| SG (1) | SG11202002186VA (https=) |
| WO (1) | WO2019077001A1 (https=) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| US12612654B2 (en) | 2016-02-12 | 2026-04-28 | CureVac SE | Method for analyzing RNA |
| US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| CN111511924A (zh) | 2017-11-08 | 2020-08-07 | 库瑞瓦格股份公司 | Rna序列调整 |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| EP3740580A4 (en) | 2018-01-19 | 2021-10-20 | Duke University | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS |
| WO2019193183A2 (en) * | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| AU2019254591B2 (en) | 2018-04-17 | 2025-12-11 | CureVac SE | Novel RSV RNA molecules and compositions for vaccination |
| WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
| CN110241116B (zh) * | 2019-05-21 | 2023-02-07 | 中国医学科学院放射医学研究所 | 一种环状rna及在促进dna损伤修复中的应用 |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| CN114502204A (zh) | 2019-08-14 | 2022-05-13 | 库尔维科公司 | 具有降低的免疫刺激性质的rna组合和组合物 |
| US20220307017A1 (en) * | 2019-08-29 | 2022-09-29 | Universität Zürich | Minimal Messenger RNAs and uses thereof |
| CN110592223B (zh) * | 2019-10-31 | 2022-10-25 | 中南大学湘雅三医院 | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 |
| CN112759652B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种嵌合抗原受体及其应用 |
| US12606822B2 (en) * | 2019-11-07 | 2026-04-21 | Icahn School Of Medicine At Mount Sinai | Synthetic modified RNA and uses thereof |
| CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US20230096704A1 (en) * | 2020-02-05 | 2023-03-30 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| EP4126030A1 (en) * | 2020-04-01 | 2023-02-08 | University Of Florida Research Foundation, Incorporated | Multilamellar rna nanoparticle vaccine against sars-cov-2 |
| CN111413498B (zh) * | 2020-04-08 | 2023-08-04 | 复旦大学附属中山医院 | 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用 |
| CA3170740A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| CN111744019B (zh) * | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| US20220017971A1 (en) * | 2020-07-15 | 2022-01-20 | Kookmin University Industry Academy Cooperation Foundation | Composition for predicting chemotherapy resistance of ovarian cancer and use thereof |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| US20230279408A1 (en) * | 2020-08-07 | 2023-09-07 | The Hong Kong University Of Science And Technology | Compositions and methods for increasing protein expression |
| US20230346921A1 (en) * | 2020-08-21 | 2023-11-02 | Peking University | Circular rna vaccines and methods of use thereof |
| EP4157344A2 (en) | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| US20230383297A1 (en) * | 2020-10-09 | 2023-11-30 | Duke University | Novel targets for reactivation of prader-willi syndrome-associated genes |
| CN112280750B (zh) * | 2020-10-22 | 2022-11-01 | 山东农业大学 | 具有跨种传播能力的新型鹅星状病毒及其应用 |
| CN112526127B (zh) * | 2020-10-28 | 2022-12-06 | 四川大学华西医院 | 一种破伤风抗原的检测方法及其应用 |
| CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| CN112574997B (zh) * | 2021-01-17 | 2023-07-21 | 楷拓生物科技(苏州)有限公司 | 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用 |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| JP2024508707A (ja) * | 2021-02-12 | 2024-02-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 熱ショックタンパク質９０結合ドメインを有する活性誘導型融合タンパク質 |
| CA3212653A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| CA3171429A1 (en) | 2021-03-31 | 2022-09-30 | Alexander SCHWENGER | Syringes containing pharmaceutical compositions comprising rna |
| CN113341152B (zh) * | 2021-04-27 | 2022-04-26 | 华南农业大学 | Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用 |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| US20240398933A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| CN115029349B (zh) * | 2022-06-09 | 2024-11-12 | 中国农业大学 | 与植物抗病性相关的circRNA、来源基因及其应用 |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
| AU2023310896A1 (en) | 2022-07-19 | 2025-01-30 | Shenzhen Shenxin Biotechnology Co., Ltd. | Mrna for sars-cov-2 s protein and use thereof |
| AU2023353931A1 (en) | 2022-09-26 | 2025-03-20 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| CN115606550B (zh) * | 2022-10-28 | 2024-01-12 | 陆华 | 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法 |
| CN120112637A (zh) * | 2022-11-11 | 2025-06-06 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
| TW202430633A (zh) * | 2022-12-07 | 2024-08-01 | 科羅拉多大學董事會法人團體 | 新穎的ｈｉｖ－１變異體及其在動物激發模型中的使用方法 |
| CN120435560A (zh) | 2022-12-16 | 2025-08-05 | 深圳深信生物科技有限公司 | 提高rna分子翻译效率和/或稳定性的utr及其应用 |
| EP4660306A1 (en) | 2023-01-31 | 2025-12-10 | Synplogen Co., Ltd. | Artificially synthesized nucleic acid for increasing protein expression |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| CN116240175B (zh) * | 2023-02-28 | 2024-02-23 | 武汉科技大学 | 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用 |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024188312A1 (en) * | 2023-03-16 | 2024-09-19 | The Hong Kong University Of Science And Technology | Compositions and methods for enhanced protein expression |
| AU2024260120A1 (en) | 2023-04-27 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| EP4713483A1 (en) | 2023-05-16 | 2026-03-25 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2025027060A1 (en) * | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025040263A1 (en) | 2023-08-24 | 2025-02-27 | CureVac Manufacturing GmbH | Purification process for in vitro amplified dna |
| JP2025082576A (ja) * | 2023-11-17 | 2025-05-29 | アンジェス株式会社 | 核酸、医薬組成物、及び核酸を製造する方法 |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025246436A1 (en) * | 2024-05-29 | 2025-12-04 | Therorna Inc. | Circular rna-based therapeutic vaccine for treating hpv positive cancer |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN101307095A (zh) | 1996-06-14 | 2008-11-19 | 明治乳业株式会社 | T细胞表位肽 |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| EP1246597B1 (en) | 1999-08-03 | 2015-01-14 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| WO2010087791A1 (en) | 2009-01-27 | 2010-08-05 | Utc Power Corporation | Distributively cooled, integrated water-gas shift reactor and vaporizer |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| US20110250264A1 (en) | 2010-04-09 | 2011-10-13 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| SI4043040T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| MX2013002332A (es) | 2010-08-31 | 2013-03-18 | Novartis Ag | Lipidos apropiados para suministro liposomal del arn que codifica la proteina. |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| MX362981B (es) * | 2012-03-27 | 2019-02-28 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
| WO2013143700A2 (en) * | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| CA2917348A1 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| RU2016109938A (ru) | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
| MY174677A (en) | 2013-08-21 | 2020-05-06 | Curevac Ag | Composition and vaccine for treating lung cancer |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| CN111304231A (zh) * | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP3233113A1 (en) | 2014-12-16 | 2017-10-25 | CureVac AG | Ebolavirus and marburgvirus vaccines |
| EP3240558A1 (en) * | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| EP3317424B1 (en) * | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
| WO2017036580A1 (en) * | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
| EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| SG10201913630YA (en) | 2016-02-17 | 2020-03-30 | Curevac Ag | Zika virus vaccine |
| WO2018104540A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| SG11201906297QA (en) * | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
-
2018
- 2018-10-17 US US16/757,289 patent/US20220233568A1/en active Pending
- 2018-10-17 MX MX2020003995A patent/MX2020003995A/es unknown
- 2018-10-17 EP EP18789606.3A patent/EP3697912A1/en active Pending
- 2018-10-17 KR KR1020257029819A patent/KR20250138817A/ko active Pending
- 2018-10-17 IL IL321714A patent/IL321714A/en unknown
- 2018-10-17 BR BR112020004351-6A patent/BR112020004351A2/pt unknown
- 2018-10-17 JP JP2020521986A patent/JP2021501572A/ja active Pending
- 2018-10-17 CA CA3073634A patent/CA3073634A1/en active Pending
- 2018-10-17 RU RU2020115287A patent/RU2020115287A/ru unknown
- 2018-10-17 WO PCT/EP2018/078453 patent/WO2019077001A1/en not_active Ceased
- 2018-10-17 SG SG11202002186VA patent/SG11202002186VA/en unknown
- 2018-10-17 KR KR1020207012300A patent/KR102858623B1/ko active Active
- 2018-10-17 CN CN201880067696.6A patent/CN111630173A/zh active Pending
- 2018-10-17 AU AU2018351481A patent/AU2018351481B2/en active Active
-
2020
- 2020-02-23 IL IL272850A patent/IL272850A/en unknown
- 2020-07-13 MX MX2026002469A patent/MX2026002469A/es unknown
-
2023
- 2023-11-06 JP JP2023189376A patent/JP2024012523A/ja active Pending
-
2025
- 2025-02-10 AU AU2025200901A patent/AU2025200901A1/en active Pending
- 2025-05-30 JP JP2025090961A patent/JP2025131658A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501572A5 (https=) | ||
| IL321714A (en) | Novel artificial nucleic acid molecules | |
| JP7762750B2 (ja) | ネオ抗原およびその使用 | |
| TWI838465B (zh) | 腫瘤免疫治療多肽及其應用 | |
| JP2020513824A5 (https=) | ||
| JP7712919B2 (ja) | マルチドメインタンパク質ワクチン | |
| JP2017525336A5 (https=) | ||
| JP2005537800A5 (https=) | ||
| US20250134971A1 (en) | Mrna for protein expression and template therefor | |
| JP2023522588A5 (https=) | ||
| Leitner et al. | Type I Interferons are essential for the efficacy of replicase-based DNA vaccines | |
| JP2021525549A5 (https=) | ||
| KR20210039376A (ko) | 개인 맞춤형 암 백신 | |
| KR20250130586A (ko) | Hpv 감염-관련 질병을 예방 또는 치료하기 위한 폴리뉴클레오티드 분자 | |
| CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
| EP3522917A2 (en) | Microbiota sequence variants of tumor-related antigenic epitopes | |
| WO2015002134A1 (ja) | 細胞性免疫誘導ワクチン | |
| US20210393757A1 (en) | Melanoma Canine Vaccine Compositions and Methods of Use Thereof | |
| JPWO2020071551A5 (https=) | ||
| CN119770633A (zh) | 一种改进型多肽肿瘤疫苗组成与应用 | |
| CN117883563B (zh) | 一种mRNA疫苗及其制备方法与应用 | |
| CN114650838B (zh) | 肿瘤特异性多肽序列及其应用 | |
| CN119792502A (zh) | mRNA疫苗及其在制备治疗肿瘤药物的应用 | |
| CN116359509A (zh) | 一种用于胃癌治疗的肿瘤新抗原筛选方法和新型纳米疫苗的制备方法及应用 | |
| CN117797253A (zh) | 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法 |